Curaleaf reported Record Pro Forma Revenue of $110.9 million

Shares :

  • Reported Record Pro Forma Revenue(1)(2) of $110.9 million and Managed Revenue(1) of $55.1 Million
  • Generated $3.4 million of Adjusted EBITDA(1) as Operations Continue to Scale 
  • Announced Acquisition of Grassroots, Inc. the Largest Private U.S. MSO for approximately $875 million Creating World’s Largest Cannabis Company and Expanding Presence to 19 States

WAKEFIELD, Mass., Aug. 27, 2019 /PRNewswire/ — Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf”or the “Company”), a leading vertically integrated cannabis operator in the U.S., today reported its financial and operating results for the second quarter ended June 30, 2019. All financial information is provided in U.S. dollars unless otherwise indicated.

Q2 2019 Financial Highlights (Unaudited)
($ thousands, except per share amounts)Q2 2019Q1 2019 % qoq 
Change
Q2 2018 % yoy 
Change
Managed Revenue(1)$55,100$40,68235%$17,294219%
Total Revenue$48,489$35,25138%$14,644231%
Gross profit before impact of biological assets$26,020$18,10744%$7,809233%
Gross profit on cannabis sales(1) $15,257$10,62444%$4,631229%
Gross margin on cannabis sales(1) 40%38%
40%
Adjusted EBITDA(1)$3,357($3,686)
($3,838)
Net income (loss) attributable to Curaleaf Holdings Inc.($24,541)($10,209)
($4,933)
Net income (loss) per share – basic and diluted($0.05)($0.02)
($0.01)
1 See “Non-IFRS Financial and Performance Measures” below for more information regarding Curaleaf’s use of Non-IFRS financial measures and other reconciliations.
2 Pro Forma Revenue includes the revenue of closed and pending acquisitions of Eureka Investment Partners, LLC (“Eureka”), Absolute Healthcare, Inc.’s Emerald Dispensary operations, Acres Cannabis (“Acres”), Phytotherapeutics Management Services, LLC, Glendale Greenhouse, Cura Partners, Inc. (“Select”) and GR Companies, Inc. (“Grassroots”) as if they occurred on January 1, 2019. 

Second Quarter Highlights

  • Reported record quarterly pro forma revenue of $110.9 million, managed revenue of $55.1 million and Adjusted EBITDA of $3.4 million 
  • Announced the acquisition of Select, the leading cannabis wholesale brand in the U.S.; Select transaction would combine Curaleaf’s retail locations, vertical integration, wellness brand and strong East Coast market presence with Select’s wholesale model, lifestyle brand and leading West Coast market presence. 
  • Acquired exclusive rights to operate Absolute Healthcare, Inc.’s Emerald dispensary in Gilbert, Arizona one of the highest grossing dispensaries in the state 
  • Announced two additional acquisitions in Arizona, both of which closed in August 2019 
    • Glendale Greenhouse, a vertically integrated cannabis operation in the Phoenix metro area 
    • Phytotherapeutics Management Services, the license of which will be applied to a newly developed flagship dispensary located at 2175 N 83rd Avenue
  • Closed on acquisitions of Eureka in Northern California and Blackjack in Las Vegas, Nevada 
  • Acquired option to purchase Ohio Grown Therapies LLC’s medical cannabis cultivation and processing licenses and facility in Ohio

Post Second Quarter Highlights

  • Announced acquisition of Chicago, Illinois-based Grassroots, the largest private U.S. MSO for approximately $875 million creating world’s largest cannabis company which will expand presence to 19 states 
  • Received approval for change of ownership and control in Massachusetts 
  • Signed a sale-leaseback agreement with Freehold Properties, Inc. for six properties valued at $28.3 million 

“We have made significant progress over the last few months in executing on our strategy to become the leading vertically integrated multi-state cannabis operator in the United States,” said Joseph Lusardi, Chief Executive Officer of Curaleaf. “The recently announced acquisitions of Select and Grassroots, as well as, tuck in acquisitionsin Arizona, California, Nevada and Ohio position Curaleaf as the undisputed leader in the cannabis industry. With the industry’s largest operational footprint, we have the scale to rapidly accelerate growth across the country. I continue to believe Curaleaf is the best positioned operator in the cannabis space with the potential to create substantial shareholder value.” 

Neil Davidson, Chief Financial Officer of Curaleaf, added,

“We achieved a number of milestones in the second quarter, foremost, we generated positive Adjusted EBITDA for the first time in Company history, and we achieved record pro forma revenue of $111 million. As our operations continue to ramp, we expect to see furtherimprovement in our overall operating margins and an improving and accelerating cash flow profile. We continue to focus on positioning ourselves as the industry leader through prudent capital allocation to deliver strong organic growth.” 

Financial Results for the Second Quarter Ended June 30, 2019

Managed Revenue for the second quarter was $55.1 million an increase of 219% over the prior year and 35% over the prior quarter. Pro Forma Revenue was $110.9 million. 

Total Revenue for the second quarter of 2019 increased 231% year-over-year to $48.5 million, compared to $14.6 million in the second quarter of 2018. Total Revenue for the second quarter of 2019 increased 38% over the prior quarter. 

Retail and wholesale revenue increased more than three-fold to $37.7 million during the quarter, compared to $11.5 million in the second quarter of 2018. The increase in retail and wholesale revenue was primarily due to organic growth in Florida resulting from opening dispensaries, the opening of two dispensaries in New York, contributions from acquisitions in Arizona and Maryland, as well as increased wholesale revenue in Massachusetts as a result of adult-use dispensaries opening in the state.

Gross profit before impact of biological assets for the second quarter of 2019 was $26.0 million, compared to $7.8 million for the second quarter of 2018. The increase was due to continued improvement in the operating capacity of the Company’s cultivation and processing facilities. 

Gross profit on cannabis sales(1) was $15.3 million in the second quarter of 2019, resulting in a 40% margin, compared to $4.6 million in the second quarter of 2018. The increase was due to the mix in retail revenue over wholesale revenue and continued improvement in the operating capacity of the Company’s cultivation and processing facilities. 

Adjusted EBITDA(1) was $3.4 million for the second quarter of 2019, compared to a loss of $3.8 million for the second quarter of 2018. 

Net loss for the second quarter of 2019 was $24.4 million, compared to a net loss of $6.4 million in the second quarter of 2018 due to an increase of $5.8 million in depreciation and amortization and an increase of $3.8 million in share-based compensation, both of which are non-cash, an increase of $4.4 million in one-time charges, primarily acquisition related, an increase of $3.4 million in net interest expense and an increase of $7.0 million in provision for income tax. Net loss per share for the second quarter of 2019 was $0.05, compared to a loss of $0.01 in the second quarter of 2018. 

Balance Sheet and Liquidity

As of June 30, 2019, we had $107.3 million of cash, $95.5 million of outstanding debt and fully diluted shares outstanding of 461.3 million.  

Conference Call and Webcast Information

Curaleaf will host a conference call and audio webcast today at 5:00 pm ET to answer questions about the Company’s operational and financial highlights. The dial-in numbers for the conference call are +1-877-407-9039 (U.S. Toll-Free) or +1-201-689-8470 (International). Please dial-in 10 to 15 minutes prior to the start time of the conference call and an operator will register your name and organization.

The conference call will also be available via webcast, which can be accessed through the Investor Relations section of Curaleaf’s website, https://ir.curaleaf.com/ir-calendar

Managed Revenue











Q2 2019

Q1 2019

Q2 2018
Total Revenue
$48,489
$35,251
$14,644
Revenue from managed entities, net of MSA fees

6,611

5,431

2,650
Managed revenue
$55,100
$40,682
$17,294




















Gross Profit on Cannabis Sales











Q2 2019

Q1 2019

Q2 2018
Retail and wholesale revenues
$37,726
$27,768
$11,466
Cost of goods sold

22,469

17,144

6,835
Gross profit on cannabis sales
$15,257
$10,624
$4,631




















Adjusted EBITDA











Q2 2019

Q1 2019

Q2 2018
Net loss 
$(24,435)
$(10,828)
$(6,430)
Interest expense, net

2,895

2,648

(488)
Income tax recovery (expense)

8,192

(1,438)

1,235
Depreciation and amortization

7,195

4,895

1,428
Share-based compensation

4,489

1,782

649
Other (income) expense

1,135

26

Change in fair value of biological assets

(1,392)

(2,246)

(1,120)
One time charges 

5,278

1,475

888
Adjusted EBITDA
$3,357
$(3,686)
$(3,838)

About Curaleaf Holdings 

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf”) is the leading vertically integrated multi-state cannabis operator in the United States. It is a high-growth cannabis company with a national brand known for quality, trust and reliability. The company is positioned in highly populated, limited license states, and currently operates in 12 states with 48 dispensaries, 14 cultivation sites and 13 processing sites. Curaleaf has the executive expertise and research and development capabilities to provide leading service, selection, and accessibility across the medical and adult-use markets, as well as in the CBD category through its Curaleaf Hemp brand. On May 1, 2019, Curaleaf announced the acquisition of the Select brand from Cura Partners for approximately $949 million. On July 17, 2019, Curaleaf announced the acquisition of Grassroots for approximately $875 million.

Condensed Interim Consolidated Statements of Financial Position (Unaudited)
($ thousands)




June 30, 
December 31,



2019
2018
Assets






Current assets:






Cash

$107,346
$266,616
Accounts receivable


14,415

9,402
Inventory, net


42,154

27,976
Biological assets


9,010

4,491
Prepaid expenses and other current assets


6,784

4,975
Total current assets


179,708

313,460
Deferred tax asset


2,556

2,556
Notes receivable


47,568

33,811
Property, plant and equipment, net


103,788

66,969
Right-of-use assets


56,165

Intangible assets, net


99,449

52,925
Goodwill


90,593

47,267
Investments


68,164

45,408
Other assets


7,070

7,440
Total assets

$655,061
$569,836








Liabilities and Shareholders’ Equity






Current liabilities:






Accounts payable

$10,376
$3,974
Accrued expenses


16,907

15,721
Income tax payable 


3,839

2,730
Current portion of lease liability


7,374

Current portion of notes payable 


8,000

Current portion of notes payable – related party


2,570

2,403
Total current liabilities


49,065

24,828
Deferred tax liability


2,895

6,508
Notes payable


84,928

81,901
Lease Liabilities


51,512

Non-controlling interest redemption liability


2,957

2,957
Contingent consideration liability 


14,475

Contingent consideration liability – related party


18,000

18,000
Total liabilities


223,833

131,194








Shareholders’ equity:






Share capital


680,987

657,525
Treasury shares


(4,663)

(4,325)
Reserves


(141,192)

(146,761)
Accumulated deficit


(100,416)

(65,666)
Total Curaleaf Holdings, Inc. shareholders’ equity


434,716

440,773
Redeemable non-controlling interest


(2,957)

(2,957)
Non-controlling interest   


(531)

(2,174)
Total shareholders’ equity


431,228

435,642
Total liabilities and shareholders’ equity

$655,061
$569,836
Condensed Interim Consolidated Statements of Profits and Losses (Unaudited)
($ thousands, except for share and per share amounts)







Three Months Ended
Six Months Ended


June 30,
June 30,


2019
2018
2019
2018
Revenues:











Retail and wholesale revenues
$37,726
$11,466
$65,494
$17,176
Management fee income

10,763

3,178

18,246

6,550
Total revenues

48,489

14,644

83,740

23,726
Cost of goods sold

22,469

6,835

39,614

11,691
Gross profit before impact of biological assets

26,020

7,809

44,126

12,035
Realized fair value amounts included in inventory sold

(15,478)

(2,871)

(25,833)

(4,336)
Unrealized fair value gain on growth of biological assets

16,870

3,991

29,471

5,957
Gross profit

27,412

8,929

47,764

13,656
Operating expenses:











Selling, general and administrative

28,029

12,535

51,298

19,834
Share-based compensation

4,489

649

6,270

1,161
Depreciation and amortization

7,195

1,428

12,091

2,544
Total operating expenses

39,713

14,612

69,659

23,539
Loss from operations

(12,301)

(5,683)

(21,895)

(9,883)
Other income (expense):











Interest income

2,436

1,702

4,919

3,157
Interest expense

(3,983)

(1,214)

(8,147)

(2,026)
Interest expense related to lease liabilities

(1,348)



(2,315)

Other expense

(1,047)



(1,073)

Total other income (expense), net

(3,942)

488

(6,616)

1,131
Loss before provision for income taxes

(16,243)

(5,195)

(28,511)

(8,752)
Income tax benefit (expense)

(8,192)

(1,235)

(6,753)

(1,012)
Net loss and comprehensive loss

(24,435)

(6,430)

(35,264)

(9,764)
Less: Net loss attributable to non-controlling interest

106

(1,497)

(513)

(2,604)
Net loss attributable to Curaleaf Holdings, Inc.
$(24,541)
$(4,933)
$(34,751)
$(7,160)
Loss per share attributable to Curaleaf Holdings, Inc. – 
basic and diluted

$(0.05)
$(0.01)
$(0.08)
$(0.02)
Weighted average common shares outstanding – 
basic and diluted


461,313,741

382,618,764

459,499,816

381,856,676

This article is written and published by The Cannabis Stock


Disclaimer : The Cannabis Stock wants to promote the cannabis market with the best publication on the market. The Cannabis Stock does not recommend selling or buying any of the company mentioned and is not responsible for any losses that may result.


Click on a star to rate this article !

Average rating / 5. Vote count:


Shares :